0001790340-26-000042
SEC filingImmuneering Corporation reported a net loss of $56.0 million for fiscal year 2025, a slight improvement from a $61.0 million loss in 2024. The company generated no revenue, with total operating expenses of $59.4 million, primarily driven by $42.0 million in research and development and $17.3 million in general and administrative costs. The net loss per share was -$1.00. The company ended the year with a strong liquidity position, holding $217.0 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations into 2029. Key forward-looking activities include the planned initiation of the Phase 3 MAPKeeper 301 trial for its lead candidate atebimetinib in mid-2026.
Immuneering Corporation is a late-stage clinical oncology company with no products approved for commercial sale and has generated no revenue from product sales. For the fiscal year ended December 31, 2025, the company reported a net loss of $56.0 million, compared to a net loss of $61.0 million for the prior year. The net loss per share attributable to common stockholders was -$1.00. Total operating expenses were $59.4 million, primarily consisting of $42.0 million in research and development costs and $17.3 million in general and administrative expenses. The company's accumulated deficit as of December 31, 2025, was $280.3 million.
The company has not generated any revenue from product sales. Its operations are financed through equity offerings and its existing cash reserves. The business model is focused on the development of novel anti-cancer medicines, specifically Deep Cyclic Inhibitors, with the lead product candidate atebimetinib in clinical trials. No segment or geographic revenue breakdown is disclosed as the company is pre-revenue.
As a pre-revenue company, traditional margin metrics like gross margin and operating margin are not applicable. The company's financial performance is measured by its net loss and operating expense management. The net loss decreased by $5.0 million year-over-year, from $61.0 million in 2024 to $56.0 million in 2025. The primary cost drivers are research and development activities for its clinical-stage oncology programs.
The company's cash flow from operating activities was -$45.3 million for the year ended December 31, 2025. Net cash used in investing activities was -$88.7 million, primarily for purchases of marketable securities. Net cash provided by financing activities was $226.6 million, largely from proceeds from the issuance of common stock. This resulted in a net increase in cash and cash equivalents of $92.5 million. The balance sheet shows total assets of $232.0 million, with $176.2 million in total current assets (including $128.6 million in cash and cash equivalents and $44.2 million in current marketable securities). Total liabilities were $13.5 million, resulting in total stockholders' equity of $218.5 million. The company held $217.0 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
Based on its current business plans, the company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund its development activities and other operations into 2029. Key near-term milestones include dosing the first patient in the Phase 3 MAPKeeper 301 trial for atebimetinib in combination with mGnP in first-line pancreatic cancer patients in mid-2026. The company also expects to present further updated circulating tumor DNA data in Q2 2026, announce updated survival data in H1 2026, and dose the first patient in a planned trial of atebimetinib in combination with Libtayo in non-small cell lung cancer patients in H2 2026. The company faces significant risks common to clinical-stage biopharmaceutical companies, including the need for substantial additional capital, uncertainties in clinical development and regulatory approval, and intense competition.